Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
1. Tenaya presented MyClimb study results at ESC on pediatric HCM. 2. 93% of participants had nonobstructive HCM with no treatment options. 3. Genotype significantly predicts risks, impacting treatment planning. 4. Preliminary data supports TN-201 as a potential therapy for HCM. 5. Urgent need for interventions in pediatric patients underscored.